RNTX (Rein Therapeutics) Loans Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rein Therapeutics Loans Receivable?

Rein Therapeutics's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Rein Therapeutics Loans Receivable Historical Data

The historical data trend for Rein Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rein Therapeutics Loans Receivable Chart

Rein Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

Rein Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Rein Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Rein Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Rein Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Rein Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rein Therapeutics Inc (NAS:RNTX) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758

Website

https://www.reintx.com

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Executives

James Brian Windsor	officer: See Remarks	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey	director	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso	director	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler	officer: See Remarks	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter	10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros	director	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H	director	C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic	officer: SVP, Chief Medical Officer	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory	officer: SVP, Chief Business Officer	305 THAYER POND ROAD, WILTON CT 06897
William Mckee	director
Nolan Howard Sigal	director	941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall	officer: VP, Finance and Operations	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd	officer: President and CEO	10445 PACIFIC CENTER CT, SAN DIEGO CA 92121